Search
Cethromycin
go.drugbank.com/drugs/DB06419Investigational[L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. … [A203369] Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment
Pramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIt was first approved by the FDA in 1997 [L5882]. … RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedIt is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the
Etoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnIt is approved in more than 60 countries worldwide but not in the US.
Fludiazepam
go.drugbank.com/drugs/DB01567IllicitInvestigationalIt is a scheduled drug in the U.S., but is approved for use in Japan.
Lomefloxacin
go.drugbank.com/drugs/DB00978ApprovedLomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Modified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalModified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc.
Pyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug